The median follow-up was 15 months (range, 4 to 29). The mean (±SD) duration of B-cell aplasia was 112±47 days. All the patients with SLE had DORIS remission, all the patients with idiopathic ...

Numerous cases and case series presented at EULAR 2024 add to a rapidly growing collection of evidence that CAR T-cell therapy will be a meaningful option in SLE and other rheumatic diseases.

Lupus is an autoimmune condition. It has a variety of symptoms and can affect many body parts. It is difficult to diagnose. Treatment can help manage symptoms.

The study initially included a total of 115 SLE patients and 115 controls, with median age 43 at baseline. Follow-up visits were scheduled at years 3, 7, and 10.

At last follow-up (4-22 months), all seven had SLE Disease Activity Index scores of 0 and were in clinical remission under Definition of Remission in SLE criteria.

Systemic lupus erythematosus (SLE) is a chronic condition that can affect multiple tissues and organs. Learn about symptoms, causes, treatments, and more.

Have been diagnosed with active SLE. Are taking at least one background therapy (immunosuppressant and/or antimalarial) for at least 12 weeks before the screening visit and must be on a stable dose ...

We conducted a phase 2 trial of litifilimab involving participants with SLE. The initial trial design called for randomly assigning participants to receive litifilimab (at a dose of 50, 150, or ...

During the 10-year follow-up, patients with SLE showed a 2.3-fold higher risk for plaque progression than healthy control participants (adjusted incidence rate ratio [aIRR], 2.26; P = .002).

Systemic lupus erythematosus (SLE) is an autoimmune disease, in which the immune system that normally protects the body from invading microbes turns against the body's own cells. Researchers ...